weight loss drugs

Penny stock Veru Inc. (NASDAQ:VERU) on Wednesday released topline safety results from the Phase 2b QUALITY study of enobosarm 3mg, enobosarm 6mg, or placebo to enhance fat loss and prevent muscle loss in patients over 60 years receiving Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide)...

Weight loss drugs have taken the world by storm and saw strong demand for the companies selling them. A new study shows that despite the increase usage of weight loss drugs, obesity is still on the rise and could hit staggering numbers in the next 25 years. What Happened: The public support of...

JPMorgan has reset the valuation for Viking Therapeutics Inc. (NASDAQ:VKTX) and Structure Therapeutics Inc. (NASDAQ:GPCR). Analyst Hardik Parikh cites several reasons for recovery, including pathways for strategic partnership with pharma, some clinical trial data points and additional clarity on...

An endorsement of a weight-loss drug by world's richest man Elon Musk could prove beneficial in the battle between two health care companies seeing revenue growth and soaring stock prices as interest in weight-loss drugs grows. What Happened: A post from Musk on Christmas shared his latest take on...

The battle for the multibillion-dollar obesity market just got fiercer. Amgen Inc's (NASDAQ:AMGN) new drug candidate, MariTide, reported promising results, helping patients shed around 20% of their body weight. But when up against the current titans — Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/...

Viking Therapeutics Inc. (NASDAQ:VKTX) is nearing a pivotal moment as its stock hovers just above a potential death cross. This ominous technical pattern, where the 50-day moving average moves below the 200-day moving average, is often seen as a bearish signal. While not confirmed yet, the...

Hims & Hers Health Inc. (NYSE:HIMS) shares fell Wednesday following an FDA update listing Novo Nordisk’s (NYSE:NVO) diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here’s what you need to know. What Happened: A report from the FDA...

Editor’s note: This story has been updated to clarify that Eli Lilly is set to report earnings premarket Wednesday. Eli Lilly and Co (NYSE:LLY) will be reporting its third-quarter earnings on Wednesday. Wall Street expects $1.45 in EPS and $12.1 billion in revenues when the company reports...

Viking Therapeutics Inc. (NASDAQ:VKTX) is set to report its third-quarter earnings on Wednesday, after the market closes. The anticipation is palpable, especially as the stock has skyrocketed almost 240% year-to-date, largely due to excitement surrounding its weight-loss drug candidate, VK2735. As...

The shortage of drugs like Novo Nordisk A/S' (NYSE:NVO) Ozempic, Wegovy, and Eli Lilly And Co's (NYSE:LLY) Mounjaro and Zepbound have fueled an illicit market of counterfeit and diverted weight loss drugs, revealing an international issue that poses significant health risks. Last week, the FDA...

Eli Lilly And Co (NYSE:LLY) is one of several companies benefitting from demand for weight loss drugs. The company is also seeing competition in the market including knockoff drugs that it said could be unsafe. What Happened: A recent report says Eli Lilly is seeking medical records of people who...

Criminals are distributing fake versions of the weight-loss drug Ozempic by forging the drug batch numbers pharmaceutical companies use to authenticate drugs and track them in a specified country. They obtain batch numbers illicitly through a liaison who works at a drugmaker factory or by buying...

Shares of the weight-loss giant Novo Nordisk A/S (NYSE:NVO) are plunging by over 6% during Wednesday morning trading in New York, in response to the quarterly results released during the premarket. What Happened: Novo Nordisk reported second-quarter 2024 sales of DKK 68.06 billion ($9.972 billion...

Over the past six months, psychologist Tom Hildebrandt has seen a surge in patients with eating disorders who are using popular weight loss drugs like Novo Nordisk A/S‘ (NYSE:NVO) Wegovy (semaglutide) or Eli Lilly And Co’s (NYSE:LLY) Zepbound (Tirzepatide). Hildebrandt, who leads Mount...

Hims & Hers Health, Inc. (NYSE:HIMS) experienced a significant decline in its stock price on Thursday. Here’s what you need to know. What To Know: The sharp drop in Hims & Hers Health shares may have been influenced by broader market reactions to news from Eli Lilly and Co (NYSE:LLY) ...